Research ArticleCancer

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

See allHide authors and affiliations

Science Translational Medicine  24 May 2017:
Vol. 9, Issue 391, eaal4682
DOI: 10.1126/scitranslmed.aal4682

Article Information

vol. 9 no. 391

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication November 24, 2016
  • Accepted for publication May 2, 2017

Author Information

  1. David P. Kodack1,*,
  2. Vasileios Askoxylakis1,*,
  3. Gino B. Ferraro1,*,
  4. Qing Sheng2,,
  5. Mark Badeaux1,
  6. Shom Goel1,,
  7. Xiaolong Qi1,§,
  8. Ram Shankaraiah1,
  9. Z. Alexander Cao2,
  10. Rakesh R. Ramjiawan1,
  11. Divya Bezwada1,
  12. Bhushankumar Patel1,
  13. Yongchul Song3,
  14. Carlotta Costa3,
  15. Kamila Naxerova1,
  16. Christina S. F. Wong1,
  17. Jonas Kloepper1,,
  18. Rita Das2,,
  19. Angela Tam2,,
  20. Jantima Tanboon4,
  21. Dan G. Duda1,
  22. C. Ryan Miller5,
  23. Marni B. Siegel6,
  24. Carey K. Anders7,
  25. Melinda Sanders8,
  26. Monica V. Estrada9,
  27. Robert Schlegel2,
  28. Carlos L. Arteaga10,
  29. Elena Brachtel4,
  30. Alan Huang2,
  31. Dai Fukumura1,
  32. Jeffrey A. Engelman3,||,** and
  33. Rakesh K. Jain1,**
  1. 1Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  2. 2Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
  3. 3Department of Medicine, MGH Cancer Center and HMS, Boston, MA 02129, USA.
  4. 4Department of Pathology, MGH and HMS, Boston, MA 02114, USA.
  5. 5Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27514, USA.
  6. 6Department of Genetics, University of North Carolina, Chapel Hill, NC 27514, USA.
  7. 7Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA.
  8. 8Department of Pathology, Microbiology, and Immunology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA.
  9. 9Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA.
  10. 10Departments of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA.
  1. **Corresponding author. Email: jain{at}steele.mgh.harvard.edu (R.K.J.); jeffrey.engelman{at}novartis.com (J.A.E.)
  • * These authors contributed equally to this work.

  • Present address: Oncology Translational Research, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.

  • Present address: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

  • § Present address: Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

  • Present address: Centre Hospitalier Universitaire Vaudois, Département de Médecine Interne, CHUV-UNIL, Rue du Bugnon 46, 1011 Lausanne, Switzerland.

  • || Present address: Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.

Altmetric

Article usage

Article usage: May 2017 to May 2019

AbstractFullPdf
May 201755148291500
Jun 20171415262495
Jul 201757669166
Aug 20174025193
Sep 20173454657
Oct 20173793980
Nov 20173185061
Dec 20172332444
Jan 20182173344
Feb 20181511540
Mar 20182023960
Apr 20181982749
May 20182092737
Jun 20181311221
Jul 20181711523
Aug 20181202725
Sep 20181201916
Oct 20181242434
Nov 20181202725
Dec 20181383017
Jan 20191125023
Feb 20191145219
Mar 20191832810
Apr 20191781822
May 20191552115